Search

everythinglearnresearchcommunity

for

Search:↓

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Bexarotene gel shows promise as a new treatment for alopecia areata.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Most people who volunteered for a health study had medical issues, showing the need for careful screening before trials.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The Annurca apple supplement significantly improved hair growth in people with hair loss.

Baricitinib was effective in treating alopecia areata in two major trials.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.